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Prevalence of Zidovudine Induced Megaloblastic Anemia among 
Human Immunodeficiency Virus Positive Patients Attending 
University of Gondar Hospital Antiretroviral Therapy Clinic, 
Northwest Ethiopia 
 
Abstract 
Background: The use of antiretroviral treatment 
containing Zidovudine in HIV infected patients is 
associated with hematological toxicity to varying degrees 
of cytopenia particularly megaloblastic anemia. However, 
there is scarcity of data which assesses prevalence of AZT 
induced megaloblastic anemia among HIV patients taking 
ART in Ethiopia.  
Objective: The aim of this study was to assess the 
prevalence of Zidovudine induced megaloblastic anemia in 
HIV/AIDS patients taking ART at University of Gondar 
Hospital, Northwest Ethiopia.  
Method: A retrospective study was conducted among 
HIV/AIDS patients who were attending Gondar University 
Hospital between January 2012 and February 2013. Data 
was collected from 319 patients’ chart and statistical 
analysis was done on SPSS version 20.  
Result: Prevalence of AZT induced anemia was 11.3% at 
the 6 month of AZT based treatment. Most of them (n = 
29, 80.6%), developed macrocytic anemia. Age shows 
significant association with the incidence of anemia (P = 
0.042) while sex, baseline CD4 cell count, presence of 
opportunistic infection, HIV clinical stage and baseline 
hemoglobin were not associated.  
 
Conclusion: This study showed high prevalence of 
macrocytic anemia after 6th months of treatment with AZT 
based ART.  
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Background 
HIV infection is frequently associated with hematological 
abnormalities such as anemia which is increasing in frequency 
and severity with progression of infection to immunologic and 
clinical AIDS [1]. Typically the anemia may result from low 
production of red blood cells, increased RBC destruction, or 
ineffective RBC production and frequently the laboratory 
features are compatible with anemia of chronic disease with a 
low reticulocyte count, normocytic normochromic red blood 
cells with normal iron stores and cytokine mediated poor 
erythropoietin response [2, 3].   
Highly active antiretroviral therapy (HAART) is used to control 
the reproduction of the virus and slow or halt the progression of 
HIV-related diseases. The introduction of HAART in 1996 with 
three antiretroviral (ARV) drugs primarily in the combination of 
one Protease Inhibitor (PI) and two Nucleoside Reverse 
Transcriptase Inhibitors (NRTIs) has led to significant reduction 
in AIDS-related morbidity and mortality [4]. Now that access to 
HAART is hopefully increasing, AZT also increasingly 
prescribed in settings with limited laboratory facilities compared 
with industrialized countries. Because generic antiretroviral 
therapy has been shown to effectively work in resource-limited 
settings selectivity of the drug is better than other regimen. AZT 
is a well-known cause of drug-induced hematotoxicity [5].  
Although different studies suggested HIV-related hematological 
complication improved with HAART regimen treatment 
including the maintenances in functional status, energy levels, 
fatigue and overall improvement in quality of life [6], HIV-
positive patients receiving highly active antiretroviral therapy 
(HAART) still develop mild to moderate anemia and associated 
quality of life impairment [7]. Especially ART regimen 
containing Zidovudine are associated with anemia with bone 
marrow suppression, where the suppression appears to be more 
common in those patients with advanced diseases, related to 
dose and duration of the treatment [8]. Drug-related anemia was 
positively associated with prescription of AZT. AZT is the 
commonest cause of drug associated anemia in which patients 
taking AZT develop anemia after 3 months of first initiation and 
consequently changing the regimen other than Zidovudine due 
to suppression of bone marrow [9] and induces megaloblastic 
anemia [10]. AZT induced Megaloblastic anemia is caused 
whenever the value of MCV is >100fl during the treatment and 
declined at a time of AZT changed to other regimen [11].   
Even if, the causes of anemia have different factors, Zidovudine 
induced megaloblastic anemia also has taken places its quotient 
at large. The research conducted on the prevalence of 
Zidovudine induced anemia in HIV patients which are 
conducted at different countries of the world showed the 
prevalence ranging from 1.3% to 95% [9]. However, most of the 
studies conducted on HAART/AZT induced anemia focus on 
general anemia. Thus, this study was conducted to assess the 
prevalence of Zidovudine induced megaloblastic anemia in HIV 
patients attending University of Gondar Hospital, Northwest 
Ethiopia. It provides information on the prevalence of 
megaloblastic anemia associated with Zidovudine treatment and 
provides information for concerned bodies to develop 
appropriate measure of reducing the risk. 
 
Methods 
Study setting and population  
A hospital based retrospective study was conducted on 319 HIV 
positive patients who were taking AZT based ART regimen and 
had a follow-up at University of Gondar Hospital ART clinic 
between January 2012 and February 2013. A patient who had 
lost follow-up and did not have full information was excluded 
from this study. Also pregnant women, patients with chronic 
kidney disease, rheumatic arthritis, cancer patients and 
gastrointestinal diseases were excluded from the study. Data 
collection sheet was used to collect the data from the patients’ 
record book. It includes initiation date of Zidovudine regimen 
with hematological parameters at baseline, at 6th months and at 
12th months. To ensure the completeness, accuracy and 
consistency of information during data collection, cross check 
before cleaning and entering the data was done. 
 
Statistical analysis  
The data obtained was coded and entered into SPSS version 20 
statistical software. Cleaning was done before the analysis of 
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the data. Descriptive statistics was used to get clear picture of 
dependent and independent variables at baseline, 6th month and 
12th month.  To determine association of anemia incidence with 
age, sex, baseline CD4 cell count, baseline hemoglobin and 
WHO clinical stage chi-square test was performed. P <0.05 was 
considered as significant.   
 
Ethical consideration 
Ethical clearance was obtained from of School of Biomedical 
and Laboratory Sciences Ethical Committee, College of 
Medicine and Health Sciences, University of Gondar before 
commencement of study. A formal letter of permission was 
submitted to University of Gondar Hospital ART Clinic and 
approved in order to conduct the research in the study sites. 
Confidentiality was kept by recoding the data with codes and 
unauthorized person didn’t have access to the data.  
Results 
A total of 319 patient charts were reviewed from ART clinic of 
University of Gondar Hospital. Of these, majority 202 (63.3%) 
were females and the mean age was 34.3+8.2 years, with age 
ranging from 19 to 65 years. About 255 (79.9%) of them were 
in the age range 25 - 44 years. Around half 162 (50.8%) of the 
patients were on WHO AIDS clinical stage III and 19 (6.0%) of 
patients were having opportunistic infection (tuberculosis). 
Nearly half of the patients’ baseline CD4 cell count was >200 
cells/μl of blood. After 6th months of AZT exposure about 160 
(50.2%) of the total study participants switched to non AZT 
based therapy (Table 1).  
 
Table 1: Characteristics of patients receiving antiretroviral therapy at ART clinic in University of Gondar Hospital, January 2012 to 
February 2013 
 
Characteristics Frequency  Percentage  
Sex Male  117 36.7 
Female 202 63.3 
Age in years  15-24 26  8.2 
25-44 255 79.9 
45-64 37  11.6 
>64 1 0.3 
WHO AIDS clinical stage  I 31 9.7 
II 101 31.7 
III 162 50.8 
IV 25 7.8 
Opportunistic infection Yes 19 6.0 
No 300 94 
Baseline CD4 cell/μl <200 162 50.8 
>200 157 49.2 
Regimen Change TDF+3TC+EFV 146 45.8 
d4T+3TC+NVP 14  4.4 
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The prevalence of AZT induced anemia among study 
population was 36 (11.3%) at the 6th month of AZT treatment. 
Of these, majority 18 (50%) of them showed mild type of 
anemia. At the 6th month of initiation of AZT, 29 (80.6%) of the 
patients developed macrocytic anemia (MCV>100) which may 
reach to 131fl and most 13 (36.1%) of the patients average 
hemoglobin concentration of red cells was normochromic 
followed by hyperchromic red cells 12 (33.3%). The prevalence, 
severity of anemia and degree of red cell macrocytosis has 
declined from 6th month of AZT treatment to the 12th month 
(Table 2).  
 
 
Table 2: Prevalence and characteristics of anemia among patients taking AZT based treatment at University of Gondar ART clinic from 
January 2012 to February 2013 
 
Variable Baseline n (%) 6 month n (%) 12 month n (%) 
Anemia            Yes  6 (1.9) 36 (11.3) 3 (0.9%) 
No 313 (98.1) 283 (88.7) 316 (99.1) 
Severity of 
anemia 
Moderate: Hgb 8 -10 g/dl 3 (0.9) 18 (50) 2 (0.6) 
Severe: Hgb < 8 g/dl 3 (0.9) 18 (50) 1 (0.3) 
MCV Normocytic : 80-100fl 4 (66.7) 7 (19.4) 2 (66.7) 
Microcytic: <80fl - -  
Macrocytic: >100fl 2 (33.3) 29 (80.6) 1 (33.3) 
MCHC Normochromic: (32-36%) 2 (33.3) 13 (36.1) 1 (33.3) 
Hypochromic : < 32% 4 (66.7) 11 (30.6) 2 (66.7) 
Hyperchromic: >36% - 12 (33.3) - 
 
 
The association between incidence of anemia after taking AZT 
based treatment with factors like age, sex, baseline CD4 cell 
count, baseline hemoglobin, presence of opportunistic infections 
and WHO clinical stage was performed but there was no 
statistical significant association between the incidence of 
anemia with all the variables except age (P =0.04) (Table 3).  
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Table 3:  Association between anemia and independent variables among HIV patients taking AZT based treatment University of Gondar 
Hospital ART clinic, January 2012 to February 2013  
 
Variables                 Anemia status  
P- value  Non anemic  Anemic  
Sex Male  106 11 0.46 
Female 177 25 
Age in years  15-24 23 3 0.042 
25-44 224 31 
45-64 36 1 
>64 0 1 
Baseline CD4 Cell/μl <200 143 19 0.86 
>200 140 17 
Opportunistic 
infection 
Yes  15 4 0.24 
No 268 32 
WHO clinical stage I 29 2 0.21 
II 91 10 
III 144 18 
IV 19 6 
Baseline hemoglobin Non anemic  279 34 0.13 
Anemic  4 2 
 
Discussion 
Since there is no specific guidance for AZT-induced anemia 
management, all antiretroviral clinics simply followed the 
National Guidelines, i.e. changing AZT to other antiretroviral 
drugs if Hgb < 6.5 g/l or in patients with severe anemia. The 
AZT induced anemia is rather unique and should be properly 
managed [12]. 
Even if the exact mechanism of the anemia is still unknown, it 
was hypothesized that AZT may suppress erythropoiesis or 
inhibit erythroid stem cells, thus causing pure red cell aplasia 
(i.e. decreased reticulocyte counts and Hgb levels without 
hemolysis or blood loss), increasing mean corpuscular volume 
(MCV) and elevating erythropoietin levels [5, 13]. In addition, 
AZT inhibits beta-globin gene expression and has bone marrow 
cytotoxicity [14]. In other hands, the experimental study 
conducted in Kentucky, USA hypothesized that AZT 
combination exposure causes immune cell populations in the 
bone marrow to undergo apoptotic cell death, and that the 
toxicity would affect the host response to an infectious stimulus 
and severe macrocytic anemia [15]. 
The prevalence of macrocytic (megaloblastic) anemia was 
higher 36 (11.3%) after initiation of AZT containing regimen at 
6th month than to baseline 6 (1.9%) and 12th month 3 (0.9%). 
About 1.9% of patient was anemic at baseline and exacerbated 
to more anemia after taking AZT containing regimen. 
Subsequently after 6th months of AZT exposure about 160 
(50.4%) of the total study participants switched to non-AZT 
containing drug and become the least anemic after 12th month of 
ART follow up. However, it seems imbalance of anemia 
between 6th month and 12th month clearly shows that AZT was 
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myelosuppressive drug due to significantly declined anemia 
successive to 6th month. 
The finding of this study was less than study from Indian, which 
shown the prevalence AZT induced anemia of 16.2% which had 
occurred within 6th months of initiation of therapy and the 
peripheral smear showed macrocytic anemia in almost half of 
the patients and in the remaining showed normocytic and 
normochromic anemia [16]. The study is not in accordance with 
this study prevalence; the reason might be the difference of 
anemia grading that we had used from management of anemia 
for chronic diseases and HIV/AIDS [11]. 
The study conducted in Uganda, reflects severe anemia was 
prevalent at ART initiation and subsequently having a new 
tuberculosis and baseline anemia were not associated with AZT 
induced anemia [17]. From saying improvement we hypothesize 
that taking Zidovudine with other ARV drugs, can reduce the 
viral load to extremely low levels, and increase the CD4 cell 
counts to promote staying healthier longer. But megaloblastic 
anemia caused by AZT was without association of these factors. 
The study was in line with our result with regard of determinant 
factors shown that there were no significant association for AZT 
induced anemia with that of 6th month hemoglobin. 
In other hand, the number of patients developed OI’s was a few; 
but the majority of WHO AIDS clinical stage were at stage III, 
which OI’s might developed next to stage IV according to 
WHO criteria. The reason of non-association of 6th month HGB 
with OI’s and clinical stage was that, both OI’s and WHO 
clinical stage data were collected for baseline. Because after 
treatment the previous stage might improves result of HAART 
and subsequently the staging system also depending treatment 
assigned as (T1 to T4). 
The highest rate of anemia was registered for 6th month (11.3%) 
and this was in line with reports from Namibia 11.3% and 
Thailand 11.2% which is in concordant with our result. From 
our result prevalence (11.3%), 29 (80.6%) of them developed 
macrocytic anemia which means, >100fl reached to 131 fl. The 
reason for having a macrocytic type of anemia might be due to 
the compensatory red cell production and early circulation of 
immature hyperchromic cells. 
One of the study conducted in Ivory Coast, revealed the 
prevalence of AZT induced anemia was 9.6%. It was somehow 
lower than the prevalence in this study. The reason for slightly 
higher prevalence of anemia in the current study might be due to 
the variation of grading of anemia.  
Most of the prevalence of AZT induced anemia was closest to 
our study. The study conducted in Southern Ethiopia in 
Hawassa referral hospital also testifies this result; prevalence 
was 12.0% which was related to this study result 11.3%. The 
specification of this study revealed the particular AZT induced 
megaloblastic anemia could help physician for management of 
anemia accordingly. The prevalence was in accordance with all 
other studies conducted in many countries that reported 4.0 to 
21.9% of anemic cases [13, 18]. Moreover, in some cases the 
anemia quickly developed; thus severe anemia was just 
detected; that was possibly due difference to patients’ socio 
demographic and study design. 
 
Conclusion 
This study higher prevalence of anemia was observed after 
taking AZT based HAART for 6th months and most of anemic 
patients showed macrocytic blood picture with mild anemia. 
There was no statistical significant association between 
incidence of anemia and independent variables (sex, baseline 
HGB, baseline CD4 cell count, presence of OI and WHO 
clinical stage).  Since the exact mechanism of AZT for causing 
anemia is not well elucidated, it will be good to conduct 
pharmacological studies for better monitoring and successful 
treatment. 
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